Cellworks Singula therapy response index (TRI) predicts clinical outcomes for esophageal adenocarcinoma: myCare-004

Computational biological modeling reveals many dysregulated signaling pathways responsible for hallmark behaviors of cancer and variable drug response in the population. A mechanistic model created for each patient using comprehensive genomic inputs can biosimulate downstream molecular effects of cell signaling and drugs for each patient’s personalized in silico virtual disease model. Singula TRI is designed to predict the outcome of specific therapies with a continuous TRI Score, 0 to 100, for each patient’s unique genomic network.

ASCO Meeting Library 2022 Esophageal Cancer